Lung cancer (non small cell, EGFR mutation positive) - afatinib NICE TAG TA310

1.1 Afatinib is recommended as an option, within its marketing authorisation, for treating adults with locally advanced or metastatic non-small-cell lung cancer only if:

• the tumour tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
• the person has not previously had an EGFR-TK inhibitor and
• the manufacturer provides afatinib with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/TA310